Login / Signup

Efficacy and Safety of Ixekizumab Through 5 Years in Moderate-to-Severe Psoriasis: Long-Term Results from the UNCOVER-1 and UNCOVER-2 Phase-3 Randomized Controlled Trials.

Craig LeonardiKristian ReichPeter FoleyHideshi ToriiSascha GerdesLyn C GuentherMelinda J GooderhamLaura K FerrisChristopher E M GriffithsHany ElMaraghyHeidi CraneHimanshu PatelRussel BurgeGaia GalloDavid ShromAnn LeungChen-Yen LinKim A Papp
Published in: Dermatology and therapy (2020)
ClinicalTrials.gov identifier, UNCOVER-1: NCT01474512, UNCOVER-2: NCT01597245.
Keyphrases
  • randomized controlled trial
  • high intensity
  • systematic review
  • study protocol
  • drug induced